The revenue beat and strong cash generation are positive, but the EPS miss and widening net loss due to non-recurring charges create a mixed picture. Monitor the company's ability to convert revenue growth into profitability and whether the new credit agreement and subordinated financing provide sufficient runway to avoid further dilution or distress.
Price Chart
Executive Summary
AMS reported Q2 2026 revenue of $8.4M (+19% YoY), beating the $7.6M consensus, but EPS of -$0.07 missed the -$0.02 estimate by 250%. The net loss widened to $514K from $280K a year ago due to $285K in legal costs and a $909K allowance for credit losses, partially offset by strong revenue growth. The company also secured a $2.0M subordinated loan from its Executive Chairman and amended its credit agreement, signaling ongoing liquidity management despite operational momentum in Direct Patient Services (+40% YoY).
Key Financial Metrics
Key Facts
- Q2 2026 revenue $8.4M (+19% YoY) vs $7.6M consensus
- EPS -$0.07 vs consensus -$0.02 (250% miss)
- Net loss attributable to AMS widened to $514K from $280K YoY
- Direct Patient Services revenue +40% YoY to $4.9M
- PBRT revenue +22% YoY to $2.3M
- Operating cash flow $4.4M in H1 2026
- Cash increased to $6.8M from $3.7M at Dec 2025
- Secured $2.0M subordinated financing from Executive Chairman entity
- Entered Third Amendment to Credit Agreement with Fifth Third Bank
- Gross margin declined to $1.4M from $1.6M YoY
- Adjusted EBITDA declined to $1.3M from $1.7M YoY
Financial Impact
Revenue beat consensus by $0.8M (+10.5%), but EPS missed by $0.05 (-250%). Net loss increased by $234K YoY due to $1.2M in one-time legal and credit allowance charges.
Risk Factors
- Widening net loss despite strong revenue growth
- Declining gross margin and adjusted EBITDA YoY
- High debt load ($16.2M current portion) relative to market cap ($10M)
- Dependence on subordinated financing from Executive Chairman
- Potential for further dilution if capital structure restructuring needed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-027549 |
| Document: asha20260812_8k.htm | 0001437749-26-027549 |
| Document: 0001437749-26-027549-index-headers.html | 0001437749-26-027549 |
| Document: 0001437749-26-027549-index.html | 0001437749-26-027549 |
| Document: 0001437749-26-027549.txt | 0001437749-26-027549 |
| 8-K Data (Synthetic) | 0001437749-26-027549 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 10w ago | 8-K | $1.60 $1.47 | ▼ −7.84% | ▼ −6.10% | $1.25 (−21.88%) |
Jul 28, 2026 12w ago | 8-K | $1.53 $1.51 | ▲ +1.31% | ▲ +6.33% | $1.25 (+18.30%) |
Jun 30, 2026 16w ago | 8-K | $1.58 $1.54 | ▼ −2.53% | ▼ −1.50% | $1.25 (−20.89%) |
May 14, 2026 23w ago | 8-K | $1.58 $1.42 | ▲ +10.13% | ▲ +9.27% | $1.25 (+20.89%) |
May 14, 2026 23w ago | Press Release | $1.58 $1.42 | ▼ −10.13% | ▼ −9.27% | $1.25 (−20.89%) |
May 7, 2026 24w ago | DEFA14A | $2.01 $1.37 | ▼ −31.84% | ▼ −34.98% | $1.25 (−37.81%) |
Apr 30, 2026 25w ago | DEFA14A | $1.45 $1.64 | ▲ +13.10% | ▲ +8.14% | $1.25 (−13.79%) |
Apr 24, 2026 26w ago | 8-K | $1.32 $1.35 | ▼ −2.27% | ▲ +2.68% | $1.25 (+5.30%) |
Mar 31, 2026 29w ago | 8-K | $1.45 $1.34 | ▲ +7.59% | ▲ +17.01% | $1.25 (+13.79%) |
Mar 31, 2026 29w ago | Press Release | $1.45 $1.34 | ▲ +7.59% | ▲ +17.01% | $1.25 (+13.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers